Search
for
Sort by
Research 481–510 of 1000+
- Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
- Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
- 12 Treatment of hirsutism with 5α-reductase inhibitors
- In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5α-reductase inhibitors
- 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction
- 5α-Reductase inhibitors, antiviral and anti-tumor activities of some steroidal cyanopyridinone derivatives
- A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma
- Mimosine Dipeptide Enantiomsers: Improved Inhibitors against Melanogenesis and Cyclooxygenase
- Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
- Alopecia associated with treatment with selective serotonin reuptake inhibitors (SSRIs)
- 5α-reductase inhibitors/finasteride
- 5α-reductase inhibitors impact prognosis of urothelial carcinoma
- Evaluation of New Pregnane Derivatives as 5.ALPHA.-Reductase Inhibitor.
- Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies
- A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia
- Synthesis and Evaluation of 2‘-Substituted 4-(4‘-Carboxy- or 4‘-carboxymethylbenzylidene)-<i>N</i>-acylpiperidines: Highly Potent and in Vivo Active Steroid 5α-Reductase Type 2 Inhibitors
- New Progesterone Esters as 5.ALPHA.-Reductase Inhibitors.
- Hedgehog Pathway Inhibitors against Tumor Microenvironment
- 5‐alpha‐reductase inhibitor treatment for frontal fibrosing alopecia: an evidence‐based treatment update
- Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review
- 5α‐Reductase inhibitors and prostatic disease
- Alopecia Diffusa while Using Interleukin-17 Inhibitors against Psoriasis Vulgaris
- Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors
- Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry
- Recent Advances in the Chemistry and Pharmacological Activity of New Steroidal Antiandrogens and 5α-Reductase Inhibitors
- 5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety
- Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
- Discovery of COVID-19 Inhibitors Targeting the SARS-CoV2 Nsp13 Helicase
- The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis
- The risk of dementia with the use of 5 alpha reductase inhibitors